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We use simple economic insights to develop a framework for distinguishing between prejudice and
statistical discrimination using observational data. We focus our inquiry on the enormous literature
in healthcare where treatment disparities by race and gender are not explained by access, preferences,
or severity. But treatment disparities, by themselves, cannot distinguish between two competing views
of provider behavior. Physicians may consciously or unconsciously withhold treatment from minority
groups despite similar benefits (prejudice) or because race and gender are associated with lower benefit
from treatment (statistical discrimination). We demonstrate that these two views can only be distinguished
using data on patient outcomes: for patients with the same propensity to be treated, prejudice implies
a higher return from treatment for treated minorities, while statistical discrimination implies that returns
are equalized. Using data on heart attack treatments, we do not find empirical support for prejudice-based
explanations. Despite receiving less treatment, women and blacks receive slightly lower benefits from
treatment, perhaps due to higher stroke risk, delays in seeking care, and providers over-treating minorities
due to equity and liability concerns.
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A vast literature in social-science and medicine finds evidence of race and gender 
disparities in wages, hiring decisions, mortgage approvals, and medical treatments. But disparities 
cannot by themselves distinguish between two competing explanations for why they exist 
[Heckman (1998) and List (2004)]: are employers, lenders, or physicians, consciously or 
unconsciously withholding jobs, loans and medical treatment from minority groups despite similar 
benefit (prejudice), or is membership in a minority group associated with lower productivity or 
benefit (statistical discrimination)? In this paper, we use simple economic insights to develop a 
framework for using observational data to distinguish between prejudice and statistical 
discrimination.
  
We focus our inquiry on the enormous literature on racial and gender disparities in 
healthcare where treatment differences are not explained by access, preferences, or severity. While 
the explanation for disparities in this context may be different than those in labor and capital 
markets, given the scope for human wellbeing and longevity it is of tremendous importance. 
Disparities in medical treatment measured using regression adjustment, audit studies and Implicit 
Association Tests (IATs) are often ascribed to prejudicial providers [Healy (1991), Bogart et al. 
(1994), Schulman et al. (1999), van Ryn and Fu (2003), Fincher et al. (2004) and Green et. al. 
(2007)]. This view is shared by the Institute of Medicine’s (IOM) Unequal Treatment report which 
concludes that provider bias was among the leading determinants of disparities (Smedley, Stith and 
Nelson, 2003).  
The key to our model is the Beckerian intuition that under taste-based prejudice, 
providers may consciously or unconsciously use a higher benefit threshold before providing care 
to minority patients (for example, recommending a treatment to non-minority patients if it 
prolongs their life by at least three months, but only treating minority patients if it prolongs their 
life by at least five months). One consequence of this type of prejudice is that minority patients 
will have higher marginal returns from being treated. Another form of bias occurs when 
providers put too much or too little weight on race and gender or misinterpret other patient 
characteristics at the time of determining appropriateness (for example, incorrectly thinking that 
a black patient who actually receives 5 months of survival benefit only receives 3 months of 
benefit). Both of these forms of prejudice, taste-based and imperfect determination of 
appropriateness, result in minority patients receiving less care than is optimal, and both predict 2 
higher benefits from treatment for minority patients. In contrast to this interpretation for why 
blacks and women (henceforth referred to as minorities) receive less care, membership in a 
minority group may predict lower benefit from treatment because of its statistical association 
with biology, pre-hospital delays, provider skill, and follow-up care. If providers are aware of the 
correlation between these factors and race and gender, the differential treatment of minorities 
may be due to statistical discrimination. While both explanations result in minority groups 
receiving less treatment, they imply vastly different policies.
1 
While it is intuitive to distinguish between the two possibilities by comparing outcomes 
for the marginal patient being treated for minority and majority groups, in the absence of 
observing exactly what the physician observes about the patient, it is impossible to identify the 
marginal patient and measure the benefit from treatment for this patient. Therefore, we address 
this complication by proposing a test for provider prejudice that relies on comparing the 
`treatment on the treated’ effect for men to women, and whites to blacks. In the absence of 
prejudice, we demonstrate that the treatment on the treated parameter is the same for both groups 
conditional on a patient’s appropriateness or propensity to receive treatment. This framework 
also allows us to ascertain whether physicians correctly determine patient appropriateness for the 
treatment. Our framework offers a test based on observational data that is complementary to that 
in List (2004) who used data from field experiments to make the distinction between prejudice 
and statistical discrimination.  
Our approach to identifying provider prejudice provides several advantages over 
ostensibly simpler methods.  Regression adjustment, audit-studies involving patient-actors, and 
Implicit Association Tests (IAT) are often used to assess the case for prejudice in lending or  
how the providers treat similar patients from different demographic backgrounds (Munnell et al. 
1996, Schulman et al., 1999, Smedley, Stith and Nelson, 2003 and Green et al., 2007). But the 
fact that providers may offer fewer treatments to women and minorities is not by itself evidence 
of prejudice—if the benefit to these groups is in fact lower on average because of lower 
appropriateness stemming from biological differences in how the treatment is absorbed, or 
                                                 
1 The literature often uses the terms prejudice, stereotyping, bias and discrimination 
interchangeably. We use the terms prejudice, animus, and bias to refer to provider behavior that 
results in allocative inefficiency. We avoid using the term stereotyping because both prejudice 
and statistical discrimination involve stereotyping—the key is whether physician behavior leads 
to greater efficiency or inefficiency in allocating treatment. We have chosen not to use the term 
discrimination to avoid confusion with the alternative hypothesis of statistical discrimination. 3 
behavioral factors such as lower compliance or ambulance delays in being taken to the hospital 
(although it could be evidence of more macro prejudice against minorities). Yet because it is 
impossible to measure outcomes for simulated patients, it is not possible to distinguish between 
the two explanations, and consequently, their very different policy implications. Similarly, it may 
be tempting to see how physicians of one race (or gender) treat patients of their demographic 
versus others, as has been done in recent studies of racial bias in motor vehicle searches 
(Antonovics and Knight, 2005; Anwar and Fang, 2006). However, this approach can only 
identify whether there is differential bias across physicians of different race, and previous 
evidence has found no difference in the how white and black physicians treat heart attack 
patients (Chen et al., 2001). Moreover, since the care of minority patients is highly concentrated 
within a small set of physicians, studies (including audit studies) that focus on whether these 
physicians treat white and black patients differently exclude the substantial number of physicians 
who only treat patients of one race. In theory, such providers may be the most or the least 
prejudicial, and patients may sort into providers in way that makes this evidence very 
unrepresentative of the discrimination being faced by a typical patient (Heckman, 1998).  
In Section II we develop the theoretical model underlying our analysis. Section III 
discusses the etiology of heart attacks and their treatments, and introduces data from the 
Cooperative Cardiovascular Project (CCP). In Section IV we detail our estimation strategy, 
paying particular attention to how the theoretical model developed in Section II will be evaluated 
using the CCP data. Section V presents results that support the statistical discrimination 
interpretation of treatment disparities. We do not find empirical support for alternative 
explanations based on prejudice or bias. If anything, despite receiving less treatment, women and 
blacks receive lower benefits, perhaps due to higher stroke risk, delays in seeking care or 
providers caring about equity or liability concerns. Differences in follow-up care or provider skill 
do not appear to explain our results. Section VII concludes. 
 
II. Theory 
  Our goal is to establish whether disparities in treatment rates represent prejudicial 
behavior by providers (implying underuse in blacks and women) or statistical discrimination 
against these groups. A simple model of patient treatment choice will guide our empirical work. 
We assume that treatment is provided to each patient whenever the expected benefit from the 4 
treatment exceeds a minimal threshold. Thus, in the terminology of Heckman, Urzua and 
Vytlacil (2006), our model allows for essential heterogeneity where the decision to provide 
treatment to each patient is made with knowledge of their idiosyncratic response to treatment.   
Within this framework, there are two ways in which a patient’s race or gender could affect 
treatment choice: race or gender could be related to the expected benefit of treatment, or could 
alter the minimal threshold that must be met to receive care.  We define taste-based prejudice to 
exist when the expected benefit from treatment for patients of a certain race or gender must 
exceed a higher threshold for them to receive treatment.  When this is the case, the treatment of 
two patients with the same expected benefit from treatment will differ because of their race or 
gender. In this situation, there is underuse of treatment for the group facing a higher threshold. In 
the absence of any prejudice, treatment will differ by race or gender only if the expected benefits 
of treatment are different.   
We illustrate this idea with the case of prejudicial behavior against women; the case for 
prejudice against blacks is analogous, with female being replaced by black. Let B represent the 
expected benefit from treatment for a given patient (benefit is the gain or improvement in 
survival relative to not receiving a treatment; not the level of survival).  We focus on the health 
benefits of the treatment, which would include any reduction in mortality or morbidity that was 
expected from the treatment, e.g. the impact of the treatment on Quality Adjusted Live Years 
(QALYs).
2  Suppose that the expected benefit from treatment depends on the patient’s gender 
(ignoring race for the moment to simplify the presentation), observable patient characteristics 
(X) such as age, medical history, and lab results (all of which are allowed to be interacted with 
gender and will be in the empirical work), and other factors that are known to the medical care 
provider when making the treatment decision but unobserved by the econometrician (ε): 
(1)        2 1 Female X B  
At this point, we are assuming that providers are not making errors in their estimation of 
patient benefit from treatment and that 1 and 2 are correctly estimated. Note that gender (or 
race) could be statistically related to the benefit of treatment in Equation (1) because of 
differences in biology, pre-existing medical conditions, follow-up care, presence of family 
                                                 
2 In principal, the benefit could also incorporate the expected impact of the treatment on the 
patient’s medical cost, and capture the health benefits net of costs. However, in our application 
the differences in treatment costs by gender and race were estimated to be small and 
insignificant, so we focus on survival for simplicity. 5 
member, or quality of the provider. Similarly, factors that are correlated with race and observed 
by providers but unobserved to the econometrician, will be absorbed into the coefficient on 
gender or race. All such differences by gender and race should be taken into account by the 
medical provider if the goal is to maximize the benefit to the patient. Thus, differences in 
treatment that arise from differences in expected benefit are not the result of prejudice in the 
current treatment decision, even though they may be the result of discrimination more broadly 
(for example, in ambulance response times or the fact that the treatment was primarily designed 
for males).  
Each patient receives treatment if the expected benefit from treatment exceeds a minimal 
threshold (τ), where the threshold can vary by gender (or race): 
(2)  2 1    Female    
Women experience prejudice if  0 2    in Equation (2), i.e. if the expected benefits must be 
higher for women to receive treatment. Equations (1) and (2) follow directly from a Roy model 
of treatment allocation, where a patient receives treatment if the gain from the treatment exceeds 
a cost hurdle of .  
Note that we assume that providers use the right index in equation (1) to determine the 
benefit from care. But providers may be using the wrong index—because of clinical uncertainty, 
or inattention, they may place undue importance on gender or use the wrong weights on key 
comorbidities. In our model, these two forms of prejudice, taste-based and imperfectly 
determining appropriateness, are identical – adding an amount to the hurdle is equivalent to 
incorrectly subtracting the same amount from the benefit when determining whether to treat a 
patient. 
  Equation (1) and (2) imply a very simple tobit structure that determines both the 
probability of treatment as well as the expected benefit conditional on being treated (the 
treatment-on-the-treated parameter).  The probability of receiving treatment is just the 
probability that expected benefits exceed the minimum threshold: 
(3)       , Pr Pr 1 Pr I B Treatment          
   1 2 2 1         Female X I where  
Equation (3) highlights why differences in treatment rates by gender (or race), holding all else 
equal, are not by themselves evidence of prejudice. Women may be less likely to receive 6 
treatment because of lower expected benefits of treatment   0 2    or because of 
prejudice 0 2   . Conversely, equation (3) demonstrates that it is premature to conclude that 
there is no prejudice against women based on estimating a coefficient of zero on female in a 
regression of treatment receipt.  Such a result could mask the fact that there is prejudice against 
minority patients  0 2    and that their benefit from treatment is higher   0 2   . Thus, contrary 
to much of the empirical literature, it is not possible to identify the effect of taste-based prejudice 
 2   from the coefficient on Female in Equation (3) alone.  
  However, the effect of prejudice can be identified if information on the treatment effect 
among the treated population is available.  The treatment-on-the-treated parameter is defined as: 
(4)       I E Female X I B E Treatment B E               | | 1 | 2 1  
Noting that Female I Female X 2 1 2 1         , we can rewrite Equation (4) as: 
(5)     , 1 | 2 I g Female Treatment B E      
     I E I I g where         | 1  
Equation (5) states that in the absence of prejudice  0 2   , two patients receiving treatment who 
have the same propensity to get the treatment (same I) will have the same expected benefit from 
the treatment.  Since the propensity to get the treatment (or equivalently the index I) can be 
estimated directly from Equation (3), we can therefore identify prejudice from an estimate of the 
treatment-on-the-treated parameter:  If there is prejudice   0 2    the treatment-on-the-treated 
effect is larger for women than it is for men with the same propensity to get treatment.     
  It is important to note that Equation (5) does not imply that the treatment-on-the-treated 
parameter is the same for all men and women in the absence of prejudice.  In fact, Equation (5) 
implies that the treatment-on-the-treated effect will tend to be larger among men if men have a 
higher propensity to be treated (since g(I) is increasing in I).  The treatment effect is the same 
only for men and women with the same propensity to be treated, or equivalently for any 
population of men and women that have the same propensity distributions (e.g. are matched on 
propensity to be treated). Formally, one can see this by noting that the average benefit to men 
and women, across all values of I may be expressed as:  
(6a) Bm = E(Benefit | Male,  I)   dF(I|Male) 
(6b) Bf =  E(Benefit | Female, I) dF(I|Female) 7 
 
Equation (6) makes it clear that even if the treatment on the treated term is identical for men and 
women of the same I, integrating this benefit over different distributions of I will result in 
finding that Bf  < Bm if women have a lower distribution of I (e.g., their characteristics make them 
less appropriate for the treatment). However, if the distributions of I are equalized for men and 
women (or whites and blacks) through reweighting, the comparison of average treatment benefits 
provides a test for prejudical providers. This is the key empirical implication that we will test in 
our empirical work. 
The above test relies on the assumption that g(I) depends only on the index, i.e. we must 
assume a single-index selectivity model, so that the truncated mean of the error in equation (5) 
depends only on the truncation point (I). This would not be the case if the distribution of the 
unobservable factors determining treatment (ε) differed by gender or by race. For example, if 
providers spend less time ascertaining a female patient’s appropriateness for treatment, then the 
variance of the ε’s () might be smaller for women. A smaller error variance for women would 
imply a lower truncated mean for any given truncation point – leading to lower expected benefits 
from treatment for women, despite facing the same threshold. This would look like prejudice 
against men (even though it is the opposite!) so it is important to rule out.  
While we will maintain the single index assumption for our primary analyses, we will 
also test its validity empirically. One test for differences in the variance of unobservables follows 
naturally from assuming normality and estimating separate probit models by gender or race for 
receiving treatment. Because probit models identify /, we would expect to observe a more 
muted relationship (smaller coefficients) between observable patient characteristics and the 
propensity to be treated for any group for which unobservable factors played a larger role in 
treatment. However, this is at best an indirect test since it relies on the assumption that the true  
is the same across groups. For example, one might believe that inattention lowers the effect of 
both observables and unobservables on treatment for minorities, so that / remains unchanged. 
Again, simply looking at the treatment propensity without estimating the benefits from treatment 
cannot clearly identify prejudice. 
An alternative test for differences in the variance of the unobservables comes from 
estimating the effect of treatment on the treated patients (Equation 5). In our model, this 
treatment-on-treated effect is simply the mean of the truncated benefit distribution that lies above 8 
the hurdle. Holding constant the proportion of patients lying above the hurdle (i.e., the propensity 
to be treated), the benefit for treated patients will tend to lie closer to the hurdle when there is 
less variance in the benefit distribution, resulting in a lower mean for the truncated distribution of 
benefits.  In addition, smaller shifts in the benefit distribution will generate larger changes in the 
proportion above the hurdle when there is less variance in the benefit distribution, resulting in a 
flatter relationship between the propensity to be treated and the mean of the truncated benefit 
distribution. Therefore, if there is less variance in the unobservable factors used to determine 
treatment for minority groups, we would expect to see both smaller benefits from treatment and 
less of a relationship between benefits and treatment propensity among minority groups.   
The graphical intuition for our model can be seen in Figure 1a for the case of no 
prejudice, and in Figure 1b for the case of prejudice against women. The expected benefit from 
treatment (B) is given on the vertical axis, while the index I (which determines the propensity of 
being treated) is given on the horizontal axis. The thick curve in Figure 1a represents the 
treatment-on-the-treated effect for a patient with index I, that is it gives      B B E | .  Treatment-
on-the-treated approaches the minimum threshold (τ) for a patient with a low propensity of being 
treated (a very negative I), since no patient is ever treated with a benefit below this threshold.  
For a patient with a high propensity of being treated (a very positive I), truncation becomes 
irrelevant and the treatment-on-the-treated effect asymptotes to the unconditional benefit of 
treatment,       I Female X 2 1 . Figure 1b shows how treatment-on-the-treated differs for 
men and women when there is prejudice against women. The treatment effect among women is 
higher at every point, reflecting the fact that the benefit of treatment must exceed a higher 
minimum threshold for women (τw> τm).  
  When there is no prejudice, as in Figure 1a, if men have a higher propensity to receive 
treatment (IM>IF), then they will also have greater benefits from treatment (BM > BF).  But in the 
absence of prejudice, any two people with the same propensity will have identical treatment 
effects if treated. In contrast, when there is prejudice, as in Figure 1b, for any two people with 
the same propensity, the group who is discriminated against (females in this example) will 
always have greater treatment effects if treated.  Thus, even if men have a higher propensity to 
receive treatment (IM>IF), they may have smaller benefits from treatment (BM < BF) if there is 
prejudice against women.  9 
  Our model shares the same notion of taste-based prejudice as Knowles, Persico and Todd 
(2001), and Balsa and McGuire (2003). In all three papers, the decision to take an action (search 
a motorist for contraband or treat a patient) is determined by whether the expected benefit 
exceeds a threshold, and prejudice exists when the threshold differs by race or gender. The 
model of racial bias in motor vehicle searches developed in Knowles et al. is conceptually 
similar to our model of prejudice, but differs in one important respect, which makes our 
empirical test of prejudice more complicated. In the Knowles et al. model, the returns to 
searching motorists in the absence of prejudice are equalized across all subgroups in equilibrium 
– otherwise, police would always search motorists with higher returns and motorists would react 
by carrying less contraband.  The key difference in our setting is that patients are not choosing 
any action analogous to carrying contraband, so there will be some subgroups of patients (those 
with high propensity to be treated) who continue to have higher returns in equilibrium even in 
the absence of prejudice. By contrast, in Knowles et al. because of an equilibrium condition that 
relies on motorists responding to the threat of being searched, there is no distinction between the 
marginal and treatment on treated effects in the absence of prejudice. Thus, in the absence of 
prejudice, the Knowles et al. model implies that the returns to search are identical across 
subgroups unconditionally, while our model implies that the returns to treatment are identical 
across subgroups conditional only on the propensity to receive treatment (I).  
  Our model differs from Balsa and McGuire (2003) in how we define statistical 
discrimination, or the alternative to prejudice. In Balsa and McGuire, statistical discrimination 
occurs when providers use different decision rules to determine a patient’s appropriateness for 
care; there is no outcomes based test. In our framework, finding evidence of these triage-rule 
differences is not informative about prejudice because it may be correct for physicians to use 
different triage rules, including using information on race and gender to determine 
appropriateness. This is analogous to how statistical discrimination is modeled by labor 
economists (Altonji and Pierret, 2001). In our framing, the test of prejudice is whether the benefit 
of treatment is larger for minority groups relative to others of the same appropriateness.  
 
III. Heart-Attacks: Biology, Treatments, and Data 
Heart-Attack Biology and Treatments 10 
 Heart attacks (more precisely, acute myocardial infarction (AMI)) occur when the heart-
muscle (the myocardium) does not receive sufficient oxygen, because of a blockage in one of the 
coronary arteries which supply blood to the heart. The blockage is typically caused by a blood 
clot that occurs because of coagulation induced by the rupture of atherosclerotic plaque inside 
the coronary arteries. Timely thrombolytics, which are also known as fibrinolytics, are 
administered intravenously and break down blood clots by pharmacological means (these drugs 
include tissue plasminogen activators, streptokinanse and urokinase). Angioplasty (where a 
balloon on a catheter is inflated inside the blocked coronary artery to restore blood flow) and 
thrombolytics are two treatments that are used for immediate reperfusion (opening up the 
coronary artery). Following the clinical literature, we define a patient to have received 
reperfusion if any of these therapies was provided within 12 hours of the heart attack (in our data 
from the mid-1990s, over 90 percent of patients receiving reperfusion received thrombolytics). 
We focus our empirical work on the treatment of AMI for a number of reasons. First, 
cardiovascular disease, of which heart attacks are the primary manifestation, is the leading cause 
of death in the US. A perusal of the leading medical journals would indicate that heart attack 
treatments are constantly being refined, and a large body of trial evidence points to significant 
therapeutic gains from many of these treatments. In this context, racial and gender disparities in 
treatments may directly translate into lost lives, and there is a rich tradition of studying racial and 
gender disparities in treatments and outcomes after heart attacks (Allison et al. (1996), Canto et 
al. (2000), Barnato et al. (2005), Vaccarino et al. (2005), Rathore et al. (2000), Skinner et al. 
(2005), Jha et al. (2007)).  
Second, as a consequence of what is known about heart attack treatments from 
randomized controlled trials, and more specifically for our setting, the benefits from reperfusion, 
we are able to assess whether our regression estimates of the benefits from reperfusion are 
comparable to those found in the medical literature, or whether they are confounded by 
selection-bias. We focus on reperfusion, where our use of chart data allows us to replicate the 
RCT evidence that is summarized by the Fibrinolytic Therapy Trialists' Collaborative Group 
(1994). 
 Third, because mortality post-AMI is high (survival rates at one year are less than 70 
percent), a well-defined endpoint is available to test the efficacy of heart attack treatments. This 11 
would not be true if we focused on treatment disparities for more chronic conditions such as 
diabetes, chronic obstructive pulmonary disease, or arthritis.  
Our fourth reason for focusing on heart attacks is that it is an acute condition for which 
virtually all patients are hospitalized and receive some medical care, thereby allowing us to 
evaluate the case for provider prejudice comprehensively. “911” operators and emergency 
medical teams are especially trained to recognize the symptoms of heart attacks. This would be 
less true of chronic diseases that progress gradually. Nor do we believe that patient preferences 
matter as much for treating heart attacks—at least during the acute phase of the heart attack the 
therapeutic emphasis is on maximizing survival, which is achieved by timely reperfusion, and 
hospital staff (not patients and their families) make treatment decisions. While providers may 
specialize in the use of surgical or medical management of heart attacks, as in Chandra and 
Staiger (2007), the fact that patients are generally taken to the nearest hospital for treatment, 
renders the nature of treatment received as exogenous to the patient preferences. This feature of 
heart attack treatments would not be true of cancer therapies where two clinically identical 
patients may chose different therapies based on their idiosyncratic valuation of side-effects and 
treatment duration.  Finally, one advantage of studying heart attacks in the Medicare population 
is that black/white differences in insurance (at least for in-hospital care) aren’t a source of 
confounding. 
Data 
Because acute myocardial infarction is both common and serious, it has been the topic of 
intense scientific and clinical interest. One effort to incorporate evidence-based practice 
guidelines into the care of heart attack patients, begun in 1992, is the Health Care Financing 
Administration's Health Care Quality Improvement Initiative Cooperative Cardiovascular Project 
(CCP). Information about more than 200,000 patients admitted to hospitals for treatment of heart 
attacks in 1994/1995 was obtained from clinical records. The CCP is considerably superior to 
administrative/claims data (of the type used by McClellan et al. (1994)) as it collects chart data 
on the patients—detailed information is provided on laboratory tests, enzyme levels, the location 
of the myocardial infarction, and the condition of the patient at the time of admission. Detailed 
clinical data were abstracted from each patient’s chart using a standard protocol. Further details 
about the CCP data are available in Marciniak et al. (1998), O’Connor et al. (1999), and in the 
appendix to this paper. The choice of sample and variables is identical to what we used and 12 
described in Barnato et al. (2005) and Chandra and Staiger (2007). 
 
IV. Estimation 
A. Basic Specifications 
We use data on heart attack treatments to estimate the key components of our model, 
using receipt of reperfusion within 12 hours of the initial heart attack as our treatment. The 
propensity to receive treatment (I in the theoretical model) is estimated by obtaining the index 
from a probit model that regresses whether a patient received reperfusion within 12 hours of the 
heart attack on gender, race, and all the CCP risk-adjusters (X): 
(7)   Pr(Reperfusioni)= F(Xi + (Female*Xi) + (Black*Xi) + (Female*Black*Xi) + ui) 
In equation (7), the effect of race and gender on the probability of receiving reperfusion is 
allowed to vary across every comorbidity. Differences in the coefficients by race or gender may 
reflect ignorance, prejudice, or actual knowledge regarding the benefits of treatment (for 
example, the effect of diabetes or age may operate differently in blacks). Alternatively, larger 
coefficients on X for women and blacks could reflect lower variance in the unobservable factors 
determining treatment (since probit models estimate /).   Finally, if providers maximize a 
different benefit in one group than another (for example, maximize survival in whites, but 
maximize survival minus costs in blacks) then we could observe different probit coefficients for 
blacks and whites. To account for these potential concerns in our empirical work, we allow for 
full gender-race interactions with X in equation 7. However, as we note in Section V, we find 
little support for these concerns in the empirical work: the predicted propensity to receive 
reperfusion from the fully interacted model was correlated 0.997 with the propensity from the 
model with no race or gender interactions. 
Our test for taste-based prejudice is to determine, among patients with the same 
propensity to be treated, whether the survival benefit to reperfusion is greater for women relative 
to men, or blacks relative to whites. Survival is measured as a binary variable that measures 
survival to a certain date (e.g. survival to 7 days, or survival to 1 year).  This suggests estimating 
models of the following type for women (equation 8a) and blacks (equation 8b), and focusing on 
the interaction term with reperfusion: 
(8a)  Survivali = α0 + α1Reperfusion + α2 (Reperfusion*Female) + X + e 
(8b)  Survivali = α0 + α1Reperfusion + α2 (Reperfusion*Black)    + X + e 13 
In equation 8a, α1 is the survival gain from reperfusion for men, α2 is the differential benefit for 
women (α1 = Bm, α2 = Bf - Bm ), and X includes full gender-race interactions (including the main 
effect of race and gender) with the CCP risk-adjusters.
3 However, as we noted in the theory 
section, α2 is estimated over different distributions of the propensity to receive reperfusion for 
men and women, and is therefore not a precise test of our model. In other words, evidence that α2 
< 0 is not sufficient evidence to conclude that there is no prejudice against women, if women are 
generally less appropriate for treatment and consequently, have lower treatment propensities. In 
the absence of prejudice, our model states that the treatment on treated (TT) effect is the same 
only for men and women with the same propensity to be treated, or equivalently for any 
population of men and women that have the same propensity distributions (e.g. are matched on 
propensity to be treated).  
To test whether the treatment-on-treated effect is the same for men and women using the 
framework of equation (8) it is key that this parameter be estimated for men and women with 
similar propensities to treated women. Therefore, we reweight the above equations at the time of 
estimation using the method of Barsky et al. (2002) to make the propensity distribution of both 
treated and untreated males (or whites) look like the propensity distribution of treated females (or 
blacks), and also reweight untreated female (or black) propensities to look like the treated female 
(or black) distribution of propensities. In other words, the treatment effect for men and women 
(or whites and blacks) is estimated for a population with the propensity distribution observed 
among the treated in the female (or black) population. We compute the weights by calculating 
the value of the 100 percentiles of the propensity distribution among treated females. By 
construction 1 percent of treated women are in each of these percentiles. Suppose that mp percent 
of one of the other three groups (treated or untreated men, or untreated women) are in the pth 
percentile of the treated female distribution of propensity. For such patients we will assign them 
a weight of 1/mp at the time of estimation. We provide evidence of the success of this strategy in 
the results section. 
B. Allowing for Treatment Effect Heterogeneity 
                                                 
3 Estimating equation (8) with claims data as opposed to chart data would cause us to 
overestimate the effect of the treatment: not only do healthier patients receive treatment, patients 
also have to survive to the point of receiving treatment (see McClellan et al., 1994 for a 
discussion). In Section V, we demonstrate that our estimates are similar to those of randomized 
clinical trials. 14 
An alternative to the reweighting strategy, which examines whether the treatment-on-
treated effect is the same for men and women (or whites and black) with the same propensity to 
be treated, is to allow the treatment effect in equation 8 to depend directly each individual’s 
propensity to be treated (i.e. to control for the interaction between the index and treatment 
directly). This requires us to estimate equations of the form:  
(9a)  Survivali = α0 + α1(Reperfusion*g(I)) + α2 (Reperfusion*Female) + X + e 
(9b)  Survivali = α0 + α1(Reperfusion*g(I)) + α2 (Reperfusion*Black)    + X + e 
In equation 9a, α1*g(I) is the survival gain from reperfusion for men, and α2 is the 
differential benefit for women. Thus, this specification allows the return to reperfusion to depend 
on g(I) for both men and women, and estimates whether women have different returns to 
reperfusion conditional on their propensity to be treated as captured by g(I). We estimate g(I) 
non-parametrically with 100 indicator variables for the percentiles of I interacted with 
reperfusion (and included directly in X), thus allowing the return to reperfusion to vary flexibly 
with a patient’s propensity to receive reperfusion. In this model, the coefficients of interest are 
those on Reperfusion*Female or Reperfusion*Black  (the direct effect of reperfusion for each 
propensity percentile would be given by the Reperfusion*Percentile indicators).
4 Moreover, we 
can recover the Reperfusion*Percentile effects to examine whether the benefits of reperfusion 
are increasing in the index (as they should if the Roy-model framework underlying our 
theoretical model is a correct assumption.) Similarly, we explore the possibility that the g(I) 
function exerts different effects on survival by gender and race.   
C. Learning from Parametric Structure  
Placing simple parametric structure on g(I) in equations 9a and 9b provides an alternative 
way to (a) evaluate whether the estimates of treatment of the treated vary by gender or race, (b)  
estimate the degree to which unobservable factors affect the benefit from treatment, and (c) 
                                                 
4 Because we have controlled for g(I) in the regression, there is no further need to reweight the 
distributions of men or whites to look like that of treated women or blacks.   15 
quantify any gender or racial differences in the importance of unobservable factors. We can 
estimate g(I) parametrically by assuming normality, which implies a tobit structure:
5 
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We calculate the last term in brackets from the estimated propensity to receive reperfusion 
(equation 7), and we allow for the two unknown parameters (τ1, σ) by including reperfusion and 
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identifies   In these models the coefficient on Reperfusion*Female or Reperfusion*Black 
continue to identify the presence of prejudice, but in a specification where the benefits to 
reperfusion are allowed to vary on the index. Moreover, because the second term picks up the 
effect of the index on the survival benefit from treatment, a positive coefficient is consistent with 
our model where providers use a single index to rank patients on the basis of their benefit from 
reperfusion, so that patients with a higher propensity to receive reperfusion also have a higher 
benefit from reperfusion.  
Finally, we explore the possibility that the g(I) function exerts different effects on 













 with gender/race. This three-way interaction provides a test of whether the variance 
in unobservable factors affecting the benefits to reperfusion (σ in equation 10) differs by gender 
or race. If unobservable factors are more important for one group, the effect of reperfusion on 
survival will depend more strongly on their propensity to receive care.  
 
                                                 
5 Equation 10 is written in terms of the index (I) estimated from the probit model. Recall that 
   , Pr 1 Pr I Treatment       and     I E I I g         | 1 . If we assume that 
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2 , 0 ~   N , then the index (I) estimated from the probit corresponds to (I
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Where the last term reflects the mean of a truncated normal.
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V. Results 
In Table 1 we report some basic characteristics of our sample by sex and race. Women 
are older than men at the time of their first heart attack, and perhaps consequently, they’re also 
substantially sicker, as measured by the presence of heart failure and hypertension. Blacks are 
younger than whites, but have significantly higher rates of heart failure, diabetes, and 
hypertension. We summarize how much sicker women and minorities are relative to men and 
whites by comparing predicted 30-day survival rates (where the prediction is made using all the 
CCP data, but not using race or gender). Predicted survival rates are similar for whites and 
blacks, and somewhat lower for women relative to men. Actual survival rates following a heart 
attack follow a similar pattern, with whites and blacks having similar survival while women have 
somewhat lower survival rates relative to men. Thus, these differences in underlying sickness 
translate into small if any difference in survival between the groups. However, there are large 
differences in actual reperfusion rates, as can be seen in the last row of Table 1. This average 
difference in the propensity to receive reperfusion between groups is the principal reason why 
estimation of equation 7 in the absence of weighting does not provide a powerful test for 
provider prejudice.  
Table 2 reports probit estimates of the effect of sex and race on the receipt of reperfusion 
within 12 hours of arriving at the hospital—marginal effects are reported in brackets. 
Unadjusted, women are 4.5 percentage points less likely to receive reperfusion, while blacks are 
6.1 percent points less likely to receive this procedure relative to whites. Adjusting for all the 
CCP risk-adjusters closes this gap for women but not for blacks. However, as noted in the theory 
section, the probit coefficients on race and sex capture both differences in the benefit from 
treatment, as well as potential differences in the treatment hurdle for these groups. As such, these 
negative coefficients do not provide us with a test of prejudice. Finally, in the last column of 
Table 2 we add a Female*Black interaction. This interaction, which is insignificant, 
demonstrates that the racial disparity in treatment does not vary by gender. 
In Table 3 we present our key results from the estimation of equation 8 for differences by 
gender (Panel A) and race (Panel B). The coefficient on Reperfusion reports the survival benefit 
of Reperfusion for men (or whites in Panel B), and the interaction effect with sex or race reports 
the differential benefit for women (and blacks in Panel B). Focusing on the unweighted results in 
Table 3, we see that Reperfusion improves the probability of surviving 30 days for men by 3.4 17 
percentage points. But for women the effect is 1.4 percentage points less. If there were underuse 
in women, we would have expected the opposite – higher returns to reperfusion for women. The 
unweighted results by race are similar. The effect of reperfusion is 2.6 percentage points less for 
blacks. Thus, the unweighted results find significantly lower effects of reperfusion for both 
blacks and women, suggesting that if anything there is overuse among blacks and women 
relative to whites and men – that is, the lower returns for blacks and women suggest that they 
face a lower hurdle in the decision to treat.  
However, as noted by our theory, this is not a sufficient test for prejudice because the 
treatment-on-the-treated effect will tend to be larger among men because men have a higher 
propensity to be treated (since g(I) is increasing in I). In column 2, we use the method of Barsky 
et al. (2002) to reweight the distributions of propensities in untreated females, treated males, and 
untreated females to resemble that of treated females. Panel B performs the analogous weighting 
for blacks. As expected, the estimated treatment effect for males and whites (the direct effect of 
reperfusion) declines after reweighting, because we are now estimating the treatment effect in a 
(reweighted) population with a lower propensity to receive treatment. Correspondingly, the 
estimated differences in the treatment effect between men and women or whites and blacks (the 
interaction of reperfusion with female or black) is smaller, and we are no longer able to reject the 
null hypothesis that the effect of reperfusion for patients receiving reperfusion is the same by 
gender and race. These weighted results are the direct test of the theoretical model, and find no 
evidence of prejudice. Prejudice and underuse would imply higher returns to treatment for 
females and blacks, but our point estimates suggest the opposite. Even the upper bound of the 
95% confidence interval on these estimates would suggest very little prejudice against females or 
blacks. 
Our estimation strategy relies on using the richness of the CCP data to invoke a `selection 
on observables’ assumption to estimate treatment on the treated for reperfusion therapy. To 
ascertain the credibility of this assumption we can compare the estimates in Table 2 to those 
obtained from clinical trials to evaluate the plausibility this assumption. A summary of nine trials 
was published in the journal Lancet by the Fibrinolytic Therapy Trialists' Collaborative Group 
(FTTCG, 1994). This was the same time-period as the CCP data and each trial evaluated 
fibrinolytic therapy in heart-attack patients. Across these nine trials, reperfusion within 12 hours 
reduces 35-day mortality by 1.9 percentage points (an 18 percent reduction in mortality). In the 18 
second column of Table 3 we estimate the effect of reperfusion (pooling across men and women) 
on 30-day survival as 1.9 percentage points (s.e.=0.2 percentage points). We focus on the second 
column because randomization balances the distribution of characteristics between the treatment 
and control arms of the trial.
6  We take this evidence as supporting the case for simpler 
regression models that invoke a ‘selection on observables’ assumption.  
In Figure 2, we examine the success of our weighting strategy to equalize the distribution 
of propensities by gender (Panel A) and by race (Panel B). The unweighted and reweighted 
propensity distributions are plotted by gender and race for the untreated (left hand side) and for 
the treated (right hand side). For reference, we have also included the propensity distribution for 
treated females (or blacks), since this is the target distribution that is being matched with 
reweighting. In the unweighted distributions, it is apparent that whites and men have higher 
propensities to receive treatment, particularly among patients receiving treatment. Therefore, our 
model would predict that unweighted estimates of the treatment effect will tend to be larger for 
whites and men, even in the absence of any prejudice. In contrast, the re-weighted distributions 
(where greater weight is put on the observations that are similar to those of the treated minority 
group) look identical to those for treated women and blacks.  
An alternative to rebalancing the distribution of propensities is to control for g(I) directly. 
In column (3) of Table 3 we include 100 indicator variables for the percentiles of I as a non-
parametric way to control for appropriateness. We also included interactions of these indicators 
with Reperfusion to test whether the benefits of reperfusion increase with g(I) (this is why we 
cannot report the direct effect of reperfusion), as they should if providers are ranking patients 
correctly and then working down the distribution of appropriateness.  The results of non-
parametric specification column (3) is identical to those obtained from propensity score 
reweighting suggesting that concerns about imperfect reweighting aren’t a source of bias. 
Moreover, in Figure 3, we plot the estimated benefit from reperfusion at every percentile of I, 
using local linear regression to smooth the effect across percentiles. The benefit from reperfusion 
is increasing with I, as is required by our model and demonstrates that physicians are able to rank 
patients so that patients who benefit most from reperfusion are most likely to receive the 
                                                 
6 Standard propensity score weighting to make the distribution of propensities for the untreated 
resemble that of the treated (that is, weighting the untreated by Pr(Reperfusion)/1-
Pr(Reperfusion)), estimates the effect of reperfusion as 2.1 percentage points which is very 
similar to the trial estimate of 1.9 points. 19 
treatment. There is evidence of ‘harm’ for patients with very low propensities of being treated 
(suggesting that the hurdle is being set at a level where survival is reduced by the treatment), but 
there are very few patients getting treatment in this range of propensities.  
In Table 4 we examine results that rely on parametric structure. In columns (1) and (2) 
we control for a (demeaned) parametric version of g(I) that was derived under the assumption of 
normality in equation (10). We demeaned the selection term in order to report estimates that are 
comparable to Table 3 – the estimated treatment effect for an average patient being treated (if the 
selection term were not demeaned, it would identify the value of the hurdle). The negative signs 
on the female/black*reperfusion variables indicate that if anything, women and blacks have 
lower benefit from treatment, but that we cannot reject the null that the benefits are the same for 
minority and non-minority patients. In these models, the interaction of reperfusion*selection 
term provides a parametric alternative to evaluating whether the benefits to reperfusion are 
increasing in physicians determination of appropriateness (which is captured by the selection 
term). The positive and significant coefficients on this interaction confirm that this is true and 
reinforce the message in Figure 3. None of these specifications alter the key results of Table 3—
in fact, the estimated effect of reperfusion and estimated difference in this effect for women and 
blacks are almost identical to what was estimated with the reweighting strategy reported in Table 
3. 
The specifications reported in Table 4, column 2 allow g(I) to have different effects on 
the benefits to reperfusion for females and blacks through the triple interaction between g(I), 
Reperfusion, and female (or black). There is no significant difference between whites and blacks: 
g(I) is associated with larger effects of reperfusion for both groups. In contrast, while the benefits 
to reperfusion are significantly increasing in g(I) for men, the effect for women is even larger. In 
the context of our model this implies that factors that are used by providers (but unobserved to 
us) play a larger role in explaining benefits for women. . We will examine this result in more 
detail in the section below. 
 
VI. Understanding Differences in Benefits 
The above results may be summarized as finding no evidence of higher returns from 
treatment for women and blacks of similar appropriateness. If anything, we have consistent but 
statistically insignificant evidence that the benefits for these groups is lower than that for men 20 
and blacks. Before concluding that this evidence represents evidence of no-prejudice, we have to 
rule out a number of other explanations. Some of these reasons may actually reflect prejudice 
and it is important to rule them out prior to concluding statistical discrimination.  
 
A. Differences in Triage Rules  
  First we consider the idea that physicians are incorrectly using different triage rules to 
rank patients (by sex or race) for treatment. If this were true, the reason for the slightly lower 
benefits for women and blacks could be that less appropriate patients from these populations 
were getting the treatment because physicians spend less time and effort in doing the triage for 
these groups. These pressures may be exacerbated by the demands of working in a high-pressure, 
time-sensitive environment where the potential for subconscious biases such as ‘implicit 
discrimination’ is high (Bertrand, Chugh and Mullainathan, 2005). In such an environment 
providers may subconsciously use a higher threshold for minority patients but also be biased in 
how patients are ranked as appropriate for care – leading to both fewer women and blacks 
receiving reperfusion and less benefit.
7 We can evaluate this concern directly by estimating 
separate probit models of receiving reperfusion by race and gender (e.g. allowing risk factors to 
have different impacts on propensity to treat by gender and race), and then examining whether 
the predicted values from this more flexible model is similar to a model in which race and gender 
enter only directly (as would be the case if they only effected the threshold). The predicted 
values are very similar, suggesting that physicians are not using different triage rules for women 
and blacks: in the full sample, the correlation between the fitted values is 0.996. For women it is 
0.993 and for males it is 0.9958. Similarly, the correlations are 0.949 for blacks and 0.998 for 
whites.
8   
The similarity of rankings from the two models also helps us rule out other forms of 
triage-bias. If providers were maximizing different dimensions of benefit in different populations 
                                                 
7 More malevolent versions of this story would involve providers offering treatment to the most 
appropriate white patients and randomly offering it to blacks, or, in the extreme, withholding it to 
the most appropriate black patients. 
8 In theory, it may be the case that on average, the common-effects model produces estimates of 
receiving reperfusion that are similar to those from the race-specific model, but there are 
significant departures in the tails of the appropriateness distribution. In Jha et al. (2007), we 
explore this possibility for a number of heart attack treatments, and note that the two models give 
very similar results across the entire distribution of appropriateness.  
 21 
(e.g. maximizing survival in blacks but survival and quality of life in whites) then the 
coefficients from the separate probits would be different and result in weakly correlated 
predictions.  
Finally, the similarity of predictions where the effects of comorbidities are allowed to 
vary by race and gender to those where they are not, supports the view that the variance of the 
unobservable characteristics (to clarify, unobserved to us, not to the physician) is similar across 
minority and majority groups (as we noted in Section IV, probit coefficients identify / so 
models estimated separately by gender and race will produce larger coefficients for the group 
with the smaller variances, i.e. the group for whom providers spend less time ascertaining 
appropriateness). However, this would be a premature assessment if providers are more likely to 
underweight all information, both the parts that are observed to us and the parts that are not, at 
the time of triaging minority patients. In this case, both the betas and the sigmas would scale 
down and the predicted effects across models with and without race and gender specific effects 
would be similar. But, as discussed in Section IV, if the variance of unobservables were smaller 
in minority groups, then the slope of curve relating treatment benefits to the propensity of 
receiving treatment would also be smaller in minority groups. However, as was seen in column 
(2) of Table 4, while women and blacks benefit less overall from reperfusion, the benefit for 
blacks and women does not depend less on their propensity – and for women appears to depend 
more on the propensity to receive reperfusion.  
 
B. Differences in Knowing Who Benefits From Treatment 
  An alternative explanation for the fact that minorities and women receive lower returns is 
that providers are unaware of how to rank patients: in other words, even though the previous 
section demonstrates that providers use the same decision rule to rank patients, they should not. 
This form of bias would occur if medical textbooks and clinical trials are biased towards 
studying the etiology of disease in whites and men, and physicians assume that this knowledge 
applies equally to women and blacks. In this case, the return to reperfusion for women or blacks 
would be lower on average, and again would depend less on their propensity to receive care (and 
could even cross, e.g., with low propensity women benefiting more from treatment than low 
propensity men). However, as was just discussed in the previous section, the benefit for blacks 
and women does not depend less on their propensity – and for women appears to depend more 22 
on the propensity to receive reperfusion. Figure 4 examines this possibility graphically by 
reporting the estimated benefit from reperfusion at every propensity to receive reperfusion, 
estimated as in Figure 3 but done separately by gender and race. The evidence in Figure 4 
demonstrates that if anything the benefits to treatment are lower for female and blacks at all 
propensities (except the very highest for females). Moreover, while estimates for blacks and 
whites are roughly parallel, the relationship between propensity and the effect of reperfusion is 
steeper for females than for males – the opposite of what we would expect if physicians were 
using the wrong decision rule to treat women.  
 
C. Differences in Follow-up Care 
Next we investigate the concern that reperfusion provides similar short-run benefits to 
blacks and women, but that a lack of follow-up care leads to worse outcomes after the patient is 
discharged from the hospital (usually within a week of the AMI). If this were the case, we would 
expect the effect of treatment on short-term mortality to be similar, while the effect of treatment 
on long-term mortality would diverge. We explore the time-path of survival in Table 5 and 
Figure 5, where we estimate separate models for survival at horizons of 3 days through 1 year. 
We find that for women, receiving reperfusion is actually associated with harm during the acute 
phase of treatment (the first 3 days). The clinical literature notes that strokes are a possible side-
effect of reperfusion, and while we cannot directly verify that women are having strokes, the 
early mortality at 3 days is consistent with this explanation. After this initial phase, there is no 
further deterioration of benefits in women; lower benefits for women are largely the consequence 
of higher acute mortality associated with reperfusion. Thus, women appear to face greater acute 
risk from the procedure, but then experience similar survival benefits in the post-acute phase. 
Blacks also experience somewhat greater mortality risk from the treatment in the acute 
phase, although the difference from whites at 3 days is not significant. In contrast to the result for 
women, however, blacks in our sample appear to receive lower (but not harmful) benefit in the 
post-acute phase—their estimated benefits of treatment remain small even at one year, and the 
gap in the treatment effect between whites and blacks continues to grow through 90 days. Thus, 
it appears that (like women) reperfusion may harm blacks more during the acute phase of 
treatment, but also (unlike women) blacks may benefit less from the treatment after the acute 
phase. One possible reason for the lack of post-acute benefit of reperfusion among blacks could 23 
be a lack of follow-up care. But another possible explanation, which we discuss further in the 
conclusion, is that blacks are known to take longer to arrive at the hospital because of ambulance 
delays and other factors, and trial evidence suggests that the effectiveness of reperfusion declines 
sharply with time since the heart attack. 
 
D. Differences in Hospital Skill 
One potential explanation for the lower benefits for blacks is that blacks and whites go to 
different hospitals, and that hospitals which treat blacks are not good at the management of heart 
attacks. This explanation is motivated by Chandra and Skinner (2004) and Skinner et al. (2005) 
who present evidence that minority serving hospitals aren’t particularly good at the management 
of heart-attacks: these hospitals exhibit lower 90-day survival for both black and white patients 
(this explanation cannot be a determinant of gender disparities in care, since men and women go 
to similar hospitals). To explore this theory, we modified equation 8 to include hospital fixed 
effects as well as hospital fixed effects interacted with whether a patient received reperfusion. 
With these fixed effects we allow hospitals to vary in quality and also in their reperfusion 
specific expertise. The estimates are reported in Table 6. Including these fixed-effects resulted in 
nearly identical estimates to the results without fixed-effects reported in Table 5, and 
demonstrates that the fact that women and minorities receive slightly lower returns is a within 
hospital phenomena.  
 
E. Differences in Cost of Treatment 
  Finally, we explored the possibility that the benefit from treatment, and therefore the 
decision to treat, may also depend on the costs of treatment.  Thinking about the costs as well as 
the health benefits of treatment is useful for two reasons. First, differences in the cost of 
treatment by race or gender may offset the survival differences, e.g. the larger impact of 
reperfusion on survival for men may be offset by higher costs of doing the procedure in men.  
Second, prejudice could appear in a more subtle form if medical care providers placed a smaller 
weight on costs in the decision to treat whites and men – implicitly placing a higher value on 24 
their life. Empirically, we found that the story about costs did not affect the results – because the 




We used a simple economic intuition to develop a framework that provides a way to 
distinguish between prejudice and statistical discrimination. Our framework relied on the 
Beckerian insight that prejudice can be ascertained by comparing outcomes for the marginal 
patient (a test that cannot be implemented without observing everything that providers observe), 
but recast this intuition by combining information on the propensity to receive treatment with 
estimates of the benefits from treatment for those patients who receive the treatment. This 
outcome-based test for prejudice is in contrast to much of the empirical literature on prejudice. 
In contrast to what models of prejudice would predict, we find that providers appear to 
know of the lower benefits that accrue to women and blacks and consequently use gender and 
race to correctly determine patient appropriateness for care. Even the upper bound of our 
estimates does not support the case for prejudice against women and blacks. In fact, if anything, 
we find that women and blacks have slightly lower benefits relative to a model of pure statistical 
discrimination. There are a number of reasons that we might observe such a pattern.  Medical 
care providers may be aware of the lower benefits of treatment in minorities, but choose to 
increase treatment rates for these groups (or lower treatment for other groups) because of 
perceived equity concerns.  This behavior may be reinforced by malpractice concerns if 
providers worry that their decision not to treat a patient based on their race or gender could 
expose them to litigation.  Alternatively, since few medical trials separately estimate the benefits 
of treatments by race or gender, medical care providers may be unaware of the extent to which 
the benefits of treatment are lower among women and minorities, or may be unwilling to make 
treatment decisions without a documented medical reason based solely on a statistical association 
                                                 
9 To perform this test, we redefined benefit as the benefit net of costs from treatment: 
C S B    , with S representing the survival benefit from treatment, and C the cost for a patient. 
λ is a measure of survival per dollar tradeoff (when λ=0, the medical care provider focuses solely 
on survival benefits). A minimum value for a life year commonly used in cost-effectiveness 
studies would be about $20k per life year, which implies a value of λ=0.01.  For reasonable 
values of λ, between 0 and .1, we were unable to reject the hypothesis that the returns to men and 
whites were similar to those for women and blacks. These results are available upon request.  
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between benefits and gender or race. In fact, the absence of such trials or medical knowledge 
may be a form of macro-prejudice against minorities (Healy, 1991), but this is a different 
explanation than bias in the clinical encounter. 
Other mechanisms for the slightly lower benefits for women and blacks are less benign. 
For example, the returns to any treatment might be low unless other treatments are also being 
provided (for example, a provider may be less likely to provide reperfusion to black patients 
knowing that they are less likely to receive other complimentary therapies such as high-quality 
diabetes care or follow-up care after discharge from the hospital), leading to an equilibrium in 
which no treatments are ever provided to minorities. While this remains a possibility, in earlier 
work we noted that racial disparities in care within hospitals and within areas are not correlated 
(see Baicker et al., 2004). For example, the racial disparity in the receipt of high-quality care was 
correlated less that 0.10 with the disparity in colorectal cancer screening or cardiac 
catheterization. The lack of correlation in disparities would suggest that explanations grounded 
in self-fulfilling equilibria are not first-order. It is also possible that lower levels of provider 
effort cause lower benefits in minorities. But we did not find evidence that providers triage 
patients into care differently, as would be the case if they used all the information at the time of 
admission for men and whites, but not for women and blacks.  
In future work it will be important to document the precise biological mechanism that 
leads to the slightly lower returns to treatment for female and black heart attack patients. For 
women, we interpret the risk of early mortality from reperfusion as evidence that they are at 
higher risk of having a stroke—and while the presence of stroke-risk is consistent with the trial 
results (see FTTCG, 1994) this would need to be established more rigorously. Such a mechanism 
suggests that alternative treatments must be developed for women that reduce the probability of 
early strokes. For blacks, lower long-term benefits from reperfusion may reflect delays in 
obtaining treatment. Sheifer et al. (2000) and Ting et al. (2008) demonstrate that it takes blacks 
longer to arrive at the hospital because of ambulance delays or because of delays in recognizing 
the symptoms of a heart attack. In our data 54 percent of whites arrived within 6 hours of the 
start of reported chest pain relative to 43 percent of blacks, and blacks were more likely to be 
coded as having no chest pain (22 percent versus 15 percent) or having unknown time since 
chest-pain at the time of arrival (9 percent versus 13 percent). Because providers do not know the 
exact status of the delay confronting minority patients they may treat black heart attacks 26 
identically to white AMIs, but doing so could result in lower benefits for black patients if they 
are less appropriate for reperfusion by virtue of their delayed arrival. Efforts to reduce late 
arrivals for minority patients are very different from those that emphasize the prejudice channel. 
The policy prescription for prejudice is to reduce underuse by performing more treatment in 
minorities or better ranking of patients for treatment. For example, the IOM’s report Unequal 
Treatment recommends increasing cultural competency for providers and hiring more minority 
physicians as ways to make progress on these channels. Under statistical discrimination, 
treatment disparities exist because of lower minority appropriateness for care. Thus, policies 
should be focused on improving their appropriateness, rather than increasing their treatment rates 
(which will only result in prejudice against the majority and could in theory even harm minority 
health). 
While we reject the role of prejudice in explaining treatment disparities for heart attacks, 
we are cautious about generalizing these conclusions to treatment disparities across all medical 
conditions. It is certainly possible that prejudice may be more pertinent in an ambulatory setting 
where patient-doctor communication is more relevant for treatment decisions. Alternatively, 
prejudice may be less relevant in ambulatory settings where the physician has more time to make 
a decision, which helps to reduce the scope for implicit bias, which is most prevalent in a time-
sensitive environment (Bertrand, Chugh and Mullainathan, 2005). Regardless of the specific 
context and explanation, our paper provides a general economic framework to evaluate the role 
of a variety of bias-based explanations for disparities in care, versus less pernicious alternatives. 
In theory, this framework can be used to assess the role of prejudice in other settings such as 
hiring, loan applications, and admissions decisions. In all of these settings, disparities in 
treatment rates alone cannot distinguish between prejudice and statistical discrimination, but can 
do so when combined with estimates of the benefits from treatment. 27 
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Construction of CCP Estimation Sample:  
The CCP used bills submitted by acute care hospitals (UB-92 claims form data) and 
contained in the Medicare National Claims History File to identify all Medicare discharges with 
an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
principal diagnosis of 410 (myocardial infarction), excluding those with a fifth digit of 2, which 
designates a subsequent episode of care.  The study randomly sampled all Medicare beneficiaries 
with acute myocardial infarction in 50 states between February 1994 and July 1995, and in the 
remaining 5 states between August and November, 1995 (Alabama, Connecticut, Iowa, and 
Wisconsin) or April and November 1995 (Minnesota); for details see O’Connor et al. (1999). 
Among patients with multiple myocardial infarction (MIs) during the study period, only the first 
AMI was examined. The Claims History File does not reliably include bills for all of the 
approximately 12% of Medicare beneficiaries insured through managed care risk contracts, but 
the sample was representative of the Medicare fee-for-service (FFS) patient population in the 
United States in the mid-1990s.  After sampling, the CCP collected hospital charts for each 
patient and sent these to a study center where trained chart abstracters abstracted clinical data.  
Abstracted information included elements of the medical history, physical examination, and data 
from laboratory and diagnostic testing, in addition to documentation of administered treatments.  
The CCP monitored the reliability of the data by monthly random reabstractions.  Details of data 
collection and quality control have been reported previously in Marciniak et al. (1998). For our 
analyses, we delete patients who were transferred from another hospital, nursing home or 
emergency room since these patients may already have received care that would be unmeasured 
in the CCP. We transformed continuous physiologic variables into categorical variables (e.g., 
systolic BP < 100 mm Hg or > 100 mm Hg, creatinine <1.5, 1.5-2.0 or >2.0 mg/dL) and included 
dummy variables for missing data.   
Our choice of variables was based on those selected by Fisher et al. (2003a,b) and 
Barnato et al. (2005). With the exception of two variables that are both measured by blood-tests, 
albumin and bilirubin (where the rates of missing data were 24 percent), we do not have a lot of 
missing data (rates were less than 3 percent). Included in our model are the following risk-
adjusters:  
Age, Race, Sex (full interactions) 
previous revascularization (1=y) 
hx old mi (1=y) 
hx chf (1=y) 
history of dementia  
hx diabetes (1=y) 
hx hypertension (1=y) 
hx leukemia (1=y) 
hx ef <= 40 (1=y) 
hx metastatic ca (1=y) 
hx non-metastatic ca (1=y) 
hx pvd (1=y) 
hx copd (1=y) 
hx angina (ref=no) 
 
hx angina missing (ref=no) 
hx terminal illness (1=y) 
current smoker 
atrial fibrillation on 
admission 
cpr on presentation 
indicator mi = anterior 
indicator mi = inferior 
indicator mi = other 
heart block on admission 
chf on presentation 
hypotensive on admission 
hypotensive missing 
shock on presentation 
peak ck missing 
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(ACC/AHA criteria) 























Figure illustrates the relationship between the expected benefit from treatment (B) on the 
vertical axis, and the index I (which determines the propensity of being treated) on the 
horizontal axis. The thick curve represents the treatment-on-the-treated effect for a patient 
with index I.  It approaches the minimum threshold (τ) for a patient with a low propensity of 
being treated.
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Figure illustrates how treatment-on-the-treated differs for men and women when there is 
prejudice against women. The treatment effect among women is higher at every point, 
reflecting the fact that the benefit of treatment must exceed a higher minimum threshold for 
women (τw> τm). Because adding an amount to the hurdle because of prejudice is equivalent 
to incorrectly subtracting the same amount from the benefit when determining whether to treat 
a patient, this is also equivalent to providers incorrectly ascertaining treatment 
appropriateness for women. 
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 Figure 2: Reweighting the Distributions of Propensities by Sex and Race 
 









Note: the unweighted and reweighted kernal densities of the probability of receiving 
reperfusion are plotted by gender (panel A) and race (panel B) for the untreated (left hand 
side) and for the treated (right hand side). For reference, we have also included the propensity 
distribution for treated females (or blacks), since this is the target distribution that is being 
matched with reweighting. All reweighting is done using the method of Barsky et al. (2002).  
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Note: Propensity to receive reperfusion is a patient’s probability of receiving reperfusion 
within 12 hours of the heart-attack. It is calculated as fitted values from a probit model that 
includes sex, race and all covariates, and all interactions with sex and race. After ranking 
patients on this index, we calculated the effect of reperfusion on survival at each percentile of 













Figure 4: Effect of Reperfusion on 30 Day Survival, by propensity to receive Reperfusion, 
and Sex and Race 
 









Note: Propensity to receive reperfusion is a patient’s probability of receiving reperfusion 
within 12 hours of the heart-attack. It is calculated as fitted values from a probit model that 
includes sex, race and all covariates, and all interactions with sex and race. After ranking 
patients on this index, we calculated the effect of reperfusion on survival using local linear 
regression using a bandwidth of 10% of the sample and a linear kernel. 37 
Figure 5: Effect of Reperfusion on Survival over Time 
 









Note: Figure reports the effect of reperfusion on the probability of survival at 3-365 days after 
the heart-attack. For each day of survival, we estimated a separate regression. The propensity 
of receive reperfusion is reweighted to resemble the distribution of treated minority patients 
(treated females in Panel A, and treated blacks in Panel B).38 
Table 1: Means by Sex and Race of Selected Variables 
 
 
 Men  Women   Whites  Blacks 
Sample Size  70,154 68,803 130,672 8,285 
          
Age 75.25 78.08   76.72 75.60 
Pr (CHF)  0.19 0.25   0.21 0.27 
Pr (Diabetes)  0.28 0.33   0.30 0.42 
Pr (Hypertension)  0.56 0.68   0.60 0.80 
    
Predicted (30 day Survival)  0.82 0.80   0.81 0.81 
    
Pr (3 day Survival)  0.92 0.90   0.91 0.92 
Pr (30 day Survival)  0.83 0.80   0.81 0.83 
Pr (360 day Survival)  0.70 0.65   0.68 0.67 
    
Pr (Reperfusion <= 12 hours)   0.21 0.16   0.19 0.12 
    
Predicted 30-day survival is a summary measure of patient sickness at the time of the heart-
attack. The prediction is made using all the CCP data, but not using race or gender. 39 
Table 2: Probit estimates of the Association between Gender and Race on the Probability of 
Receiving Reperfusion with 12 Hours 
 


































      
N 138,957  138,957  138,957 
 
Note: Dependent variable is the whether patient received reperfusion within 12 hours. Table 
reports probit coefficients with marginal effects evaluated at the point of full sample means in 
square-brackets. Probit model includes all CCP risk-adjusters, but does not allow for further 
interactions between sex, race and these covariates. 40 
 
Table 3: Gender and Race Differences in 30 day Survival from Reperfusion within 12 Hours, 












 (1)  (2)   
A: Gender Difference      
      
Reperfusion   0.034  0.024   
 (0.003)  (0.003)   
      
Reperfusion*Female -0.014  -0.010  -0.009 
    (0.005)  (0.006)  (0.005) 
      
      
N 138,957  138,957  138,957 
      
      
      
B: Race Difference      
      
Reperfusion   0.029  0.013   
 (0.003)  (0.003)   
      
Reperfusion*Black -0.026  -0.020  -0.019 
    (0.012)  (0.012)  (0.012) 
      
      
N 138,957  138,957  138,957 
 
Note: Results for each column and in each panel are from a linear regression in which the 
dependent variable is a dummy for 30-day survival, and that controls for sex, race and all 
covariates, and all interactions with sex and race. Regression in column (2) reweights 
everyone using the method of Barsky et al. (2002) to look like treated females (Panel A) or 
treated blacks (Panel B). Column 3 includes 100 percentiles of I interacted with the receipt of 
Reperfusion. Robust standard errors reported in parentheses.  41 
 
Table 4: Gender and Race Differences in 30 day Survival from Reperfusion within 12 Hours, 
OLS Estimates using Parametric and Non-Parametric Controls for Propensity to Receive Reperfusion 
 
 
    Parametric g(I) 
 
Parametric g(I) 
    
 (1)  (2)     
A: Gender Difference        
        
Reperfusion   0.023  0.024     
 (0.003)  (0.003)     
        
Reperfusion*Female -0.009  -0.008     
    (0.005)  (0.005)     
        
Reperfusion*Selection Term  0.147  0.097     
    (0.016)  (0.021)     
        
Reperfusion*Selection Term*Female   0.124     
   (0.034)     
        
N 138,957  138,957     
        
        
B: Race Difference        
        
Reperfusion   0.013  0.013     
 (0.003)  (0.003)     
        
Reperfusion*Black -0.019  -0.016     
    (0.012)  (0.012)     
        
Reperfusion*Selection Term  0.148  0.147     
 (0.016)  (0.017)     
        
Reperfusion*Selection Term*Black    0.000     
   (0.091)     
        
N 138,957  138,957     
 
Note: Results for each column and in each panel are from a linear regression in which the dependent variable is 
a dummy for 30-day survival, and that controls for sex, race and all covariates, and all interactions with sex 
and race. The parametric selection term in columns (1) and (2) is (demeaned) I+(I)/(I). Robust standard 
errors reported in parentheses.  
Table 5: Gender and Race Differences in the Effect of Reperfusion within 12 hours on 
Survival at Different Time-points, OLS Estimates 
 
Survival at:  3-day  7-day 30-day  90-day  360-day 
        
A: Gender Difference        
        
Reperfusion    -0.004 0.009 0.024 0.032 0.045 
  (0.003) (0.003) (0.003) (0.004) (0.004) 
       
Reperfusion*Female  -0.016 -0.012 -0.010 -0.009 -0.005 
  (0.004) (0.005) (0.006) (0.006) (0.006) 
       
N  138,957 138,957 138,957 138,957 138,957 
       
       
B: Race Differences       
       
Reperfusion   -0.020  -0.004  0.013  0.023  0.039 
  (0.002) (0.003) (0.003) (0.003) (0.004) 
       
Reperfusion * Black  -0.006  -0.015  -0.020  -0.030  -0.023 
    (0.009)  (0.010)  (0.012)  (0.013)  (0.015) 
        
N  138,957 138,957 138,957 138,957 138,957 
        
Note: Results for each column and in each panel are from a linear regression in which the 
dependent variable is a dummy for survival as indicated, and that controls for sex, race and all 
covariates, and all interactions with sex and race. Regression reweight everyone using the 
method of Barsky et al. (2002) to look like treated females (Panel A) or treated blacks (Panel 
B). Robust standard errors reported in parentheses.   43 
 
Table 6: Gender and Race Differences in the Effect of Reperfusion within 12 hours on Survival 
at Different Time-points, OLS Estimates with Hospital and Hospital Expertise Fixed-Effects 
 
Survival at:  3-days  7-days 30-days  90-days  360-days 
        
A: Gender Gap in Benefit        
        
Reperfusion*Female  -0.017 -0.013 -0.010 -0.009 -0.005 
  (0.004) (0.005) (0.006) (0.006) (0.006) 
       
Hospital  FE    Yes Yes Yes Yes Yes 
Hospital  FE  *  Reperfusion  Yes Yes Yes Yes Yes 
       
N  138,957 138,957 138,957 138,957 138,957 
       
       
B: Race Gap in Benefit        
       
Reperfusion  *  Black  -0.010 -0.019 -0.020 -0.027 -0.039 
  (0.009) (0.010) (0.012) (0.012) (0.014) 
        
Hospital  FE    Yes Yes Yes Yes Yes 
Hospital  FE  *  Reperfusion  Yes Yes Yes Yes Yes 
        
N  138,957 138,957 138,957 138,957 138,957 
 
Note: Results for each column and in each panel are from a linear regression in which the 
dependent variable is a dummy for survival as indicated. Controls are included for sex, race 
and all covariates, and all interactions with sex and race, along with hospital and 
hospital*reperfusion fixed effects. Regression reweight everyone using the method of Barsky 
et al. (2002) to look like treated females (Panel A) or treated blacks (Panel B). Robust 
standard errors reported in parentheses. 
 